Clinical effects of growth hormone on bone: A review

Aging Male

Volumn 7, Issue 4, 2004, Pages 290-296

  Kann, P H ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Bone; Growth hormone

Indexed keywords

GLUCOCORTICOID; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; INTERLEUKIN 6; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TURNOVER; CANCER RISK; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDICATION; DRUG SAFETY; DRUG UTILIZATION; FRACTURE; GROWTH HORMONE DEFICIENCY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

BONE DENSITY; BONE REMODELING; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; OSTEOPOROSIS;

EID: 11244319582     PISSN: 13685538     EISSN: None     Source Type: Journal    
DOI: 10.1080/13685530412331284632     Document Type: Review

References (75)

1. Kann P, Piepkorn B, Schehler B, et al. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol 1998;48:561-8
2. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev 1998;10:55-79
3. Amato G, Carella C, Fazio S, et al. Body composition, body metabolism and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Met ab 1993;77:1671-6
4. Amato G, Izzo G, La Montagna G, Bellastella A. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clin Endocrinol 1996;45:27-32
5. Sartorio A, Conti, A, Monzani M. New markers of bone and collagen turnover in children and adults with growth hormone deficiency. Postgraduate Med J 1993;69:846-50
6. Bing-You RG, Denis MC, Rosen CJ. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone response to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calcif Tissue Int 1993;52:183-7
7. De Boer H, Blok GJ, van Lingen, A, Teule GJ, Lips P, van der Veen EA. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994;9:1319-26
8. Elgindy N, Grunditz, R, Thoren M, Degerblad M, Sjöberg HE, Ringertz H. Longterm follow-up of metacarpal cortical thickness and bone mineral density in panhypopituitarism. Radial Diag 1991; 32:326-30
9. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult-onset growth hormone deficiency. J Clin Endocrinol Metab 1994;78:669-74
10. Kann P, Piepkorn B, Schehler B, et al. Replacement therapy with recombinant human growth hormone (GH) in GH-deficient adults: effects on bone metabolism and bone mineral density in a 2-year prospective study. Endocrinol Metab 1995; 2:103-10
11. Kaufman JM, Taelman P, Vermeulen A, Vandeweghe M. Bone mineral status in growth hormone deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1992;74:118-23
12. Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson B-A. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol 1993;129:201-6
13. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, et al. Increased fracture rate in adults with growth hormone deficiency. Endocrinol Metab 1996;3:121
14. Wuster C, Slenczka E, Ziegler R. Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution? Klin Wochenschr 1991;69:769-73
15. Wuster C, Abs R, Bengtsson BA, et al. for KIMS Study Group and the KIMS International Board. Pharmacia & Upjohn International Metabolic Database. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001;16:398-405
16. Ahmad AM, Thomas J, Clewes A, et al. Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism. J Clin Endocrinol Metab 2003;88:2860-8
17. Balducci R, Toscano V, Pasquino AM, et al. Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapy. Eur J Endocrinol 1995;132:42-6
18. Beshyah SA, Thomas E, Kyd P, Sharp P, Fairney A, Johnston DG. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism. Clin Endocrinol 1994;40:383-91
19. Beshyah SA, Kyd P, Thomas E, Fairney A, Johnston DG. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults. Clin Endocrinol 1995;42:249-54
20. Degerblad M, Elgindy N, Hall K, Sjöberg H-E, Thoren M. Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocrinol 1992;126:387-93
21. Hansen TB, Brixen K, Vahl N, et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab 1996;81:3352-9
22. Vandeweghe M, Taelman P, Kaufman JM. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol 1993;39:409-15
23. Ernst M, Froesch ER. Growth hormone dependent stimulation of osteoblast-like cells in serum-free cultures via local synthesis of insulin-like growth factor I. Biochem Biophys Res Commun 1988;151:142-7
24. Maor G, Hochberg Z, Von der Murk K, Heinegard D, Silberman MM. Human growth hormone enhances chondrogenesis and osteogenesis in a tissue culture system of chondro-progenitor cells. Endocrinology 1992;125:1239-45
25. Nishiyama K, Sugimoto T, Kaji H, Kanatani M, Kobayashi T, Chihara K. Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation. Endocrinology 1996;137:35-41
26. Slootweg MC, van Buul-Offers SC, Herrmann-Erlec MPM, van der Meer JM, Duursma SA. Growth hormone is mitogenic for fetal mouse osteoblasts but not for undifferentiated bone cells. J Endocrinol 1988;116:R11-13
27. Stracke H, Schulz A, Moeller D, Rossol S, Schatz H. Effect of growth hormone on osteoblasts and demonstration of somatomedin-C IGF-1 in bone organ culture. Acta Endocrinol 1984;107:16-24
28. Abrahamsen B, Hangaard J, Horn HC, et al. Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies. Clin Endocrinol 2002;57:273-81
29. Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996;125:883-90
30. Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res 2002;17:1081-94
31. Degerblad M, Bengtsson BA, Bramnert M, et al. Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. Eur J Endocrinol 1995;133:180-8
32. Finkenstedt G, Gasser RW, Hofle G, Watfah C, Fridrich L. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up. Eur J Endocrinol 1997;136:282-9
33. Gomez JM, Gomez N, Fiter J, Soler J. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement. Horm Metab Res 2000;32:66-70
34. Holmes SJ, Whitehouse RW, Swindell R, Economou G, Adams JE, Shalet SM. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin Endocrinol 1995;42:627-33
35. Sneppen SB, Hoeck HC, Kollerup G, Sorensen OH, Laurberg P, Feldt-Rasmussen U. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults - an 18-month randomised, placebo-controlled, double blinded trial. Eur J Endocrinol 2002;146:187-95
36. Johannsson G, Rosen T, Bosacus I, Sjöström L, Bengtsson B-A. Two years growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996; 81:2865-73
37. Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumber BMD. Clin Endocrinol 2004;60:175-84
38. Shalet SM, Shavrikova E, Cromer M, et al. Effect of growth Hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 2003;88:4124-9
39. Dennison EM, Hindmarsh PC, Kellingray S, Fall CH, Cooper C. Growth hormone predicts bone density in elderly women. Bone 2003;32:434-40
40. Rico H, Del-Rio A, Vila T, Patino R, Carrera F, Espinos D. The role of growth hormone in the pathogenesis of postmenopausal osteoporosis. Arch Intern Med 1979;139:1263-5
41. Dequeker J, Burssens A, Boullion R. Dynamics of growth hormone secretion in patients with osteoporosis and in patients with osteoarthrosis. Horm Res 1982;16:353-6
42. Li G, Zeng M. Relation of serum growth hormone and estradiol levels and osteoporosis in postmenopausal women. Chung Hua Tsa Chin Taipei 1990;70:16-19
43. Rubin CD. Southwestern internal medicine conference: growth hormone - aging and osteoporosis. Am J Med Sci 1993;305:120-9
44. Kassem M, Brixen K, Blum W, Mosekilde I, Eriksen EF. No evidence for reduced spontaneous or growth hormone stimulated serum levels of insulin-like growth factor (IGF)-1, IGP-II or IGF binding protein 3 in women with spinal osteoporosis. Eur J Endocrinol 1994;131:150-5
45. Johansson AG, Eriksen EF, Lindh E, et al. Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men. J Clin Endocrinol Metab 1997;82:2795-8
46. Kurland BS, Chan PK, Rosen CJ, Bilezikian JP. Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 1998;83:2576-9
47. Gillberg P, Johansson AG, Blum WF, Groth T, Ljunghall S. Growth hormone secretion and sensitivity in men with idiopathic osteoporosis. Calcif Tissue Int 2001;68:67-73
48. Kruse HP, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res 1975;7:488-91
49. Aloia JF, Zanzi I, Ellis K, et al. Effects of growth hormone in osteoporosis. J Clin Endocrinol Metab 1976;43:992-9
50. Aloia JF, Vaswani A, Kapoor A, Yeh JK, Cohn SH. Treatment of osteoporosis with calcitonin, with and without growth hormone. Metabolism 1985;34:124-9
51. Aloia JF, Vaswani A, Meunier PJ, et al. Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin. Calcif Tissue Int 1987;40:253-9
52. Brixen K, Kassem M, Eriksen EF, Nielsen HK, Flyvbjerg A, Mosekilde L. Growth hormone (GH) and adult bone remodelling: the potential use of GH in treatment of osteoporosis. J Pediatr Endocrinol 1993;6:65-71
53. Eriksen EF, Kassem M, Brixen K. Growth hormone and insulin-like growth factors as anabolic therapies for osteoporosis. Horm Res 1993;40:95-8
54. Kassem M, Brixen K, Mosekilde I, Eriksen EF. Human marrow stromal osteoblast-like cells do not show reduced responsiveness to in vitro stimulation with growth hormone in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994;54:1-6
55. Kassem M, Brixen K, Blum W, Mosekilde I, Eriksen EF. Normal osteoclastic and osteoblastic response to exogenous growth hormone in patients with postmenopausal spinal osteoporosis. J Bone Miner Res 1994;9:1365-70
56. Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T, Chihara K. Effect of recombinant human growth hormone in elderly osteoporotic women. Clin Endocrinol 1999;51:715-24
57. Sugimoto T, Kaji H, Nakaoka D, et al. Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis. Eur J Endocrinol 2002;147:339-48
58. Saaf M, Hilding A, Thoren M, Troell S, Hall K. Growth hormone treatment of osteoporotic postmenopausal women - a one year placebo-controlled study. Eur J Endocrinol 1999;140:390-9
59. Erdtsieck RJ, Pols, HA, Valk NK, et al. Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial. Clin Endocrinol 1995;43:557-65
60. Gonnelli S, Cepollaro C, Montomoli M, et al. Treatment of postmenopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study. Clin Endocrinol 1997;46:55-61
61. Johansson AG, Lindh E, Blum WF, Kollerup G, Sorensen OH, Ljunghall SJ. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1996;81:44-8
62. Gillberg P, Mallmin H, Petren-Mallmin M, Ljunghall S, Nilsson AG. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab 2002;87:4900-6
63. Papanicolaou DA, Wilder RL, Manolagos SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-37
64. Franco P, Marelli O, Lattuada D, Locatelli V, Cocchi D, Muller EE. Influence of growth hormone on the immunosuppressive effect of prednisolone in mice. Acta Endocrinol Copenh 1990;123:339-44
65. Ortoft G, Oxlund H. Qualitative alterations of cortical bone in female rats after long-term administration of growth hormone and glucocorticoid. Bone 1996;18:581-90
66. Swolin-Eide D, Nilsson A, Ohlsson C. Cortisol increases growth hormone-receptor expression in human osteoblast-like cells. J Endocrinol 1998; 156:99-105
67. Giustina A, Bussi AR, Jacobello C, Wehrenberg WB. Effects of recombinant growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 1995;80:122-9
68. Ott SM, Aitken ML. Osteoporosis in patients with cystic fibrosis. Clin Chest Med 1998;19:555-67
69. Tanaka H, Seino Y. Does growth hormone treatment prevent corticosteroid-induced osteoporosis? Bone 1996;18:493-4
70. Brill KT, Weltman AL, Gentili A, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab 2002;87:5649-57
71. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6
72. Renehan AG, O'Connell J, O'Halloran D, et al. Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res 2003;35:712-25
73. Mucci LA, Tamimi R, Lagiou P, et al. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 2001;87:814-20
74. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847-53
75. Giovannucci E, Pollak M, Platz EA, et al. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study. Growth Horm IGF Res 2000;10SupplA:S30-31